Pfizer Inc. (PFE) Stock: Price, Forecast & Analyst Target
Pfizer Inc. (PFE) — MoonshotScore 68/100 (Strong band), calculated Oct 6, 2026. Price $27.41 (-1.40%), as of the Oct 5, 2026 trading session; market cap $156B. Expected results Nov 3, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 13.33× (market value Oct 5, 2026; cash Jun 28, 2026) · expected results Nov 3, 2026
Pfizer Inc. · PFE · NYSE · Healthcare · Drug Manufacturers - General
Research dated 2026-09-12: Pfizer sells medicines and vaccines across oncology, cardiovascular care, infectious disease, rare disease, immunology and other therapeutic areas, chiefly through its Biopharma business. Its future depends on whether newer products, collaborations and manufacturing savings can counter pressure on established brands while preserving cash generation. Recent revenue and operating profit improved, but the latest period still ended in a net loss and produced much less operating cash than preceding periods.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore v2 · Pfizer (PFE)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, at a cheap price, but a strained balance sheet and weak growth; the market is already moving on it. Business Quality: Elite; Financial Safety: Strained; Valuation: Fair; Growth Durability: Fading; Momentum: Rising.
- quarterly revenue $15.03B (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 8 of 8
- expected results Nov 3, 2026
Holding back: balance-sheet strain, soft growth
Helping: business quality, an attractive price, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 68 | Strong | |
| 68 | Strong | |
| 68 | Strong | |
| 68 | Strong | |
| 68 | Strong | |
| 68 | Strong |
The score was 68 in the stored Oct 5, 2026 snapshot and remains 68 in the current publication computed Oct 6, 2026 (0); the largest pillar moves were Momentum -2 and Financial Safety +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $27.41 | |
| Change on the day | -1.40% | |
| 52-week range | $23.62 – $29.21 | |
| Market capitalisation | $156B | |
| Price / earnings (trailing) | 36.22 | |
| Shares traded on the day | 32.35M | |
| Beta (volatility vs the S&P 500) | 0.3 | |
| Dividends per share (last 12 months) | $1.72 | |
| Dividend yield (last 12 months) | 6.28% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
We also expect post-2028 cash flow to benefit from the previously announced Vyndamax patent settlement.
Cecile Guegan · Statement from
Separately, the next phase of our multiyear manufacturing optimization program is designed to reduce cost of goods sold and deliver approximately $1.5 billion in additional net cost savings, and we expect to begin realizing a portion of this saving in 2027.
Cecile Guegan · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsCouncil Score · weighted blend of 2 available disciplines
Council score for Pfizer (PFE): Bullish Lean
65/100 · B+Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 6, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the PFE film — every key number, told as a short cinematic story
~2 min · open the film
What is Pfizer (PFE), and what does it report?
Short answer · as of
Pfizer develops, manufactures and distributes prescription drugs, biologics, vaccines, biosimilars, sterile injectables and anti-infectives.
Research dated 2026-09-12.
Pfizer develops, manufactures and distributes prescription drugs, biologics, vaccines, biosimilars, sterile injectables and anti-infectives. Demand arrives through prescriptions, administered doses and institutional purchases by wholesalers, pharmacies, hospitals, clinics, governments and public-health organizations; contract manufacturing adds a smaller activity alongside proprietary products and collaborations.
The breadth of the portfolio does not translate into a broad set of separately reported operating segments. Reported revenue is overwhelmingly assigned to Biopharma, with only a comparatively small corporate reconciling category, so the segment totals mainly measure the performance of one aggregated medicines-and-vaccines portfolio rather than distinct divisional businesses.
What do the latest results show for Pfizer (PFE)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $15.03B.
Research dated 2026-09-12.
The latest period delivered higher revenue, gross profit and operating profit than the immediately preceding period and the comparable earlier period. Yet the income statement moved from profit to loss as research and development and selling, general and administrative costs rose from the preceding period. Operating cash flow remained positive but weakened sharply, leaving only modest cash generation after capital spending.
The earnings figure tracked against market estimates remained positive and exceeded expectations, while the statutory income statement recorded a loss. Those presentations should not be treated as interchangeable. Management separately says manufacturing optimization is intended to lower production costs and deliver additional savings, but that is an outlook for future efficiency rather than an explanation for the latest accounting loss.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $15.03B Jun 28, 2026
- Latest quarter · R&D
- $2.81B Jun 28, 2026
- Latest quarter · SG&A
- $3.41B Jun 28, 2026
- Latest quarter · FMP standardized operating result
- $4.71B Jun 28, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 28, 2026 | $15.03B | $2.81B | $3.41B | $4.71B |
| Mar 29, 2026 | $14.45B | $2.63B | $2.96B | $4.03B |
| Dec 31, 2025 | $17.56B | $3.42B | $3.73B | $3.69B |
| Sep 28, 2025 | $16.65B | $3.94B | $3.19B | $3.55B |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $15.03B Aug 4, 2026
- Latest report · revenue estimate
- $14.40B Aug 4, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 4, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 4, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 4, 2026 | $15.03B | $14.40B | $0.7700 | $0.6820 |
| May 5, 2026 | $14.45B | $13.84B | $0.7500 | $0.7220 |
| Feb 3, 2026 | $17.56B | $16.85B | $0.6600 | $0.5670 |
| Nov 4, 2025 | $16.65B | $16.50B | $0.8700 | $0.6330 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $15.03B | -$246M | -$0.04 (diluted) |
| Q1 FY2026 | $14.45B | $2.69B | $0.47 (diluted) |
| Q4 FY2025 | $17.56B | -$1.65B | -$0.29 (diluted) |
| Q3 FY2025 | $16.65B | $3.54B | $0.62 (diluted) |
What are the financial strengths and risks for Pfizer (PFE)?
Short answer
Cash and short-term investments were $11.70B at the Jun 28, 2026 balance-sheet date. Operating cash flow was $835.00M for the quarter ended Jun 28, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-12.
Pfizer still generates substantial operating cash across the reporting cycle, and its trailing free-cash-flow yield is stronger than its trailing earnings yield. Liquidity also covers current liabilities on the broader current-asset measure, although the more restrictive quick measure is thinner.
Debt greatly exceeds cash and investments, while cash and short-term investments have declined across the latest consecutive reporting periods. That makes sustained cash conversion more important than headline profit alone. A setback across major brands such as Eliquis, Ibrance, Vyndaqel, Paxlovid, Comirnaty or Prevnar would feed directly into the dominant Biopharma revenue pool; contract manufacturing and corporate reconciling activity do not provide meaningful segment diversification.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $835.00M Jun 28, 2026
- Previous quarter · operating cash flow
- $2.62B Mar 29, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 28, 2026 | $835.00M | −$533.00M |
| Mar 29, 2026 | $2.62B | −$436.00M |
| Dec 31, 2025 | $5.35B | −$845.00M |
| Sep 28, 2025 | $4.60B | −$602.00M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Pfizer (PFE)?
Short answer · as of
The next earnings report is expected on Nov 3, 2026.
Research dated 2026-09-12.
The next earnings release should be read across revenue, statutory net income, the estimate-tracked earnings measure and operating cash flow. Recent estimate beats have not prevented volatility in statutory earnings or a sharp slowdown in cash generation, so confirmation requires those measures to improve together.
Watch whether manufacturing savings begin to appear in gross and operating margins, whether the cash balance stabilizes, and whether consensus revenue expectations stop moving downward across the longer forecast horizon. Management also expects the Vyndamax patent settlement to support cash flow beyond the nearer forecast period; until then, product performance and cost execution carry the burden.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
We also expect post-2028 cash flow to benefit from the previously announced Vyndamax patent settlement.
Cecile Guegan ·
Separately, the next phase of our multiyear manufacturing optimization program is designed to reduce cost of goods sold and deliver approximately $1.5 billion in additional net cost savings, and we expect to begin realizing a portion of this saving in 2027.
Cecile Guegan ·
How does Pfizer compare with its peers?
Short answer
Pfizer's score ranks tied for 4th of 6 in the bounded comparison shown, against 5 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Pfizer combines mass-market vaccines and anti-infectives with oncology drugs, rare-disease therapies, cardiovascular medicines, biosimilars, sterile injectables and contract manufacturing. Its commercial exposure therefore spans pharmacy dispensing, hospital use, physician prescribing and government or public-health procurement, while collaborations place some products inside shared economics rather than a purely self-owned portfolio.
That operating variety is consolidated into an overwhelmingly Biopharma reporting structure. Comparisons based only on segment count can therefore misread Pfizer: the diversification lies inside its product portfolio, therapeutic areas, customers and partnerships, not across separately disclosed operating divisions.
| Company | Price | Market value | Score |
|---|---|---|---|
| $37.54 Oct 5, 2026 | $167B | 91 5-pillar Oct 6, 2026 | |
| $402.98 Oct 5, 2026 | $217B | 85 5-pillar Oct 6, 2026 | |
| $139.54 Oct 5, 2026 | $345B | 74 5-pillar Oct 6, 2026 | |
| Pfizer (PFE) — this page | $27.41 | $156B | 68 |
| $221.21 Oct 5, 2026 | $156B | 68 5-pillar Oct 6, 2026 | |
| $144.63 Oct 5, 2026 | $179B | 64 5-pillar Oct 6, 2026 | |
| $58.81 Date unavailable | $120B | — Model unavailable | |
| $156.25 Date unavailable | $242B | — Model unavailable | |
| $39.51 Date unavailable | $94.9B | — Model unavailable | |
| $46.55 Date unavailable | $93.3B | — Model unavailable | |
| $140.53 Date unavailable | $267B | — Model unavailable | |
| $265.76 Date unavailable | $470B | — Model unavailable | |
| $252.93 Date unavailable | $610B | — Model unavailable |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $26.00 – $31.00
- Consensus target
- $28.50
- Median target
- $28.50
Consensus record · Captured .
Measured against a quoted price of $27.41 (as of Oct 5, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Sep 30, 2026
- Transactions
- 42
- Identified insiders
- 13
- Purchases
- 3
- Sales
- 2
- Other transactions
- 37
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 67.9% Period end Jun 30, 2026
- Previous quarter · ownership
- 66.2% Prior to period end Jun 30, 2026
- Reporting holders
- 2,957 Period end Jun 30, 2026
- Previous quarter · holders
- 3,092 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 529,670,433 |
| Vanguard Capital Management LLC | 372,149,852 |
| State Street Corp | 307,090,897 |
| Geode Capital Management, LLC | 135,275,782 |
| Vanguard Portfolio Management LLC | 119,235,030 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Pfizer (PFE)?
What Investors Ask About Pfizer (PFE) — Healthcare
Research dated 2026-09-12; the answers below are from that research, and the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
Why can Pfizer beat earnings expectations while reporting a net loss?
The estimate-tracked earnings series and the statutory income statement present different earnings measures. In the latest period, the former was positive and above consensus while diluted statutory earnings and net income were negative, so the apparent contradiction comes from comparing unlike presentations.
How important is Pfizer contract manufacturing beside Biopharma?
Contract manufacturing broadens Pfizer’s activities, but the reported segment structure remains overwhelmingly Biopharma. It does not appear as a separately material segment in the disclosed revenue split.
What does the Vyndamax patent settlement mean for Pfizer cash flow?
Management expects the settlement to benefit cash flow beyond the nearer forecast period. It therefore supports the longer-term cash outlook but does not resolve the recent weakening in operating cash generation.
Can Pfizer manufacturing savings offset the expected revenue decline?
Manufacturing savings can lower cost of goods sold and support margins or cash flow, but they do not replace lost sales. The relevant test is whether margin improvement and cash conversion strengthen while consensus revenue expectations eventually stabilize.
What is the PFE stock price today?
The last price recorded on this page for Pfizer Inc. (PFE) is $27.41, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the PFE price target?
The analyst consensus price target for Pfizer Inc. (PFE) is $28.50 (range $26.00 to $31.00, median $28.50), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
When are PFE's next earnings?
The next earnings date listed on this page for Pfizer Inc. (PFE) is Nov 3, 2026. Companies sometimes move report dates, so the company's own announcement is the final word on timing.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (84 figures)
The 84 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Cecile Guegan (Aug 4, 2026): We also expect post-2028 cash flow to benefit from the previously announced Vyndamax patent settlement. Cecile Guegan (Aug 4, 2026): Separately, the next phase of our multiyear manufacturing optimization program is designed to reduce cost of goods sold and deliver approximately $1.5 billion in additional net cost savings, and we expect to begin realizing a portion of this saving in 2027. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | NEW York, NY | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "66 Hudson Boulevard East, New York City, NY, 10001-2192, US". |
FMP — 72 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $27.41 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-06T06:04:38.451Z. | |
px.change | Change on the day | -1.40% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $156B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-05. FMP quote timestamp: 2026-10-05T19:59:59.000Z. Captured from FMP at 2026-10-06T06:04:38.226Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.39 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $15.03B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.pe | Price / earnings (trailing) | 36.22 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 32.35M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.3 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Albert Bourla | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 75,000 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $81.29B, net result $22.15B; FY2022 revenue $100.33B, net result $31.36B; FY2023 revenue $59.55B, net result $2.13B; FY2024 revenue $63.63B, net result $8.02B; FY2025 revenue $62.58B, net result $7.77B | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Biopharma Segment $61.20B · Segment Reporting, Reconciling Item, Corporate Nonsegment $1.38B | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 71.3% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-28.revenue_k | Revenue — period end 2026-06-28 | $15.03B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-28.rd_k | R&D — period end 2026-06-28 | $2.81B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-28.sga_k | SG&A — period end 2026-06-28 | $3.41B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-28.operating_result_k | FMP standardized operating result — period end 2026-06-28 | $4.71B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-29.revenue_k | Revenue — period end 2026-03-29 | $14.45B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-29.rd_k | R&D — period end 2026-03-29 | $2.63B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-29.sga_k | SG&A — period end 2026-03-29 | $2.96B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-29.operating_result_k | FMP standardized operating result — period end 2026-03-29 | $4.03B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $17.56B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $3.42B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $3.73B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | $3.69B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-28.revenue_k | Revenue — period end 2025-09-28 | $16.65B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-28.rd_k | R&D — period end 2025-09-28 | $3.94B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-28.sga_k | SG&A — period end 2025-09-28 | $3.19B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-28.operating_result_k | FMP standardized operating result — period end 2025-09-28 | $3.55B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-04.revenue_actual | Revenue · reported — report date 2026-08-04 | $15.03B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-04.revenue_estimated | Revenue · estimate — report date 2026-08-04 | $14.40B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-04.eps_actual | EPS · reported — report date 2026-08-04 | $0.7700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-04.eps_estimated | EPS · estimate — report date 2026-08-04 | $0.6820 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.revenue_actual | Revenue · reported — report date 2026-05-05 | $14.45B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.revenue_estimated | Revenue · estimate — report date 2026-05-05 | $13.84B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.eps_actual | EPS · reported — report date 2026-05-05 | $0.7500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.eps_estimated | EPS · estimate — report date 2026-05-05 | $0.7220 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-03.revenue_actual | Revenue · reported — report date 2026-02-03 | $17.56B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-03.revenue_estimated | Revenue · estimate — report date 2026-02-03 | $16.85B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-03.eps_actual | EPS · reported — report date 2026-02-03 | $0.6600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-03.eps_estimated | EPS · estimate — report date 2026-02-03 | $0.5670 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.revenue_actual | Revenue · reported — report date 2025-11-04 | $16.65B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.revenue_estimated | Revenue · estimate — report date 2025-11-04 | $16.50B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.eps_actual | EPS · reported — report date 2025-11-04 | $0.8700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.eps_estimated | EPS · estimate — report date 2025-11-04 | $0.6330 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $11.70B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $835.00M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-28. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $1.56B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $63.19B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 1.83× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-28.operating_cash_flow_m | Operating cash flow — period end 2026-06-28 | $835.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-29.operating_cash_flow_m | Operating cash flow — period end 2026-03-29 | $2.62B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-28.capex_m | Capital expenditure (reported) — period end 2026-06-28 | −$533.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-29.capex_m | Capital expenditure (reported) — period end 2026-03-29 | −$436.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $5.35B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$845.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-28.operating_cash_flow_m | Operating cash flow — period end 2025-09-28 | $4.60B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-28.capex_m | Capital expenditure (reported) — period end 2025-09-28 | −$602.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $26.00 – $31.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $28.50 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $28.50 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 42 transactions · 3 purchases, 2 sales, 37 other transactions · 13 identified insiders · of the newest 60 records, those within the last 180 days, newest dated Sep 30, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 67.9% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 66.2% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 2,957 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 3,092 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Blackrock, INC. — shares in provider snapshot | 529,670,433 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Vanguard Capital Management LLC — shares in provider snapshot | 372,149,852 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | State Street Corp — shares in provider snapshot | 307,090,897 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Geode Capital Management, LLC — shares in provider snapshot | 135,275,782 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Vanguard Portfolio Management LLC — shares in provider snapshot | 119,235,030 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 3, 2026 | UNRECORDED | Stored earnings-calendar observation — Captured 2026-09-30 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 8 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-06 | |
px.range52 | 52-week range | $23.62 – $29.21 | UNRECORDED | Stored company-profile observation — Captured 2026-10-06 |
COMPUTED — 5 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 13.33× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $11.70B at Jun 28, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-05. Balance-sheet reference date: 2026-06-28. The inputs do not establish a single common source date for this ratio. |
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $1.72 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 4 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-06, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 6.28% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-08-04.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($15.03B) with the recorded estimate ($14.40B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-04.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.7700) with the recorded estimate ($0.6820) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 68 of 100 · Strong · pillars 85 / 33 / 68 / 33 / 76 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 68 (stored snapshot Oct 5, 2026) → 68 (current publication computed Oct 6, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-28. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-28.revenue_k,fin.q_table.depth.2026-06-28.rd_k,fin.q_table.depth.2026-06-28.sga_k,fin.q_table.depth.2026-06-28.operating_result_k,fin.q_table.depth.2026-03-29.revenue_k,fin.q_table.depth.2026-03-29.rd_k,fin.q_table.depth.2026-03-29.sga_k,fin.q_table.depth.2026-03-29.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-28.revenue_k,fin.q_table.depth.2025-09-28.rd_k,fin.q_table.depth.2025-09-28.sga_k,fin.q_table.depth.2025-09-28.operating_result_k. - Earnings-history note. Source series as of 2026-08-04. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-04.revenue_actual,earn.history.depth.2026-08-04.revenue_estimated,earn.history.depth.2026-08-04.revenue_actual.comparison,earn.history.depth.2026-08-04.eps_actual.comparison,earn.history.depth.2026-08-04.eps_actual,earn.history.depth.2026-08-04.eps_estimated,earn.history.depth.2026-05-05.revenue_actual,earn.history.depth.2026-05-05.revenue_estimated,earn.history.depth.2026-05-05.eps_actual,earn.history.depth.2026-05-05.eps_estimated,earn.history.depth.2026-02-03.revenue_actual,earn.history.depth.2026-02-03.revenue_estimated,earn.history.depth.2026-02-03.eps_actual,earn.history.depth.2026-02-03.eps_estimated,earn.history.depth.2025-11-04.revenue_actual,earn.history.depth.2025-11-04.revenue_estimated,earn.history.depth.2025-11-04.eps_actual,earn.history.depth.2025-11-04.eps_estimated. - Cash-flow note. Source series as of 2026-06-28. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-28.operating_cash_flow_m,fin.opcf.depth.2026-03-29.operating_cash_flow_m,fin.opcf.depth.2026-06-28.capex_m,fin.opcf.depth.2026-03-29.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-28.operating_cash_flow_m,fin.opcf.depth.2025-09-28.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | Biopharma Segment: $61.20B; Segment Reporting, Reconciling Item, Corporate Nonsegment: $1.38B | 2025-12-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-28 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-28 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Management outlook — dated call excerpts | Captured record · 2 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-08-04 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-12 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-08-04 | FMP | Financial Modeling Prep (FMP) earnings |
| Most recent periodic reports | 2026-08-04 | OFFICIAL | SEC EDGAR filer submissions | |
| Cash, investments and debt | Total debt: $63.19B; Liquidity basis: cash and short-term investments; Total liabilities: $115.64B; Cash and short-term investments: $11.70B; Cash and investments: $13.26B; Long-term investments: $1.56B; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-28 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $13.26B; Cash and short-term investments: $11.70B; Long-term investments: $1.56B; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-28 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-28 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash against market value | As of: 2026-06-28; Cash basis: cash and short-term investments; Net cash: -$51.49B; Total debt: $63.19B; Cash and investments: $11.70B Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-28 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Trailing twelve-month ratio set | Quick ratio: 0.96; Current ratio: 1.27; Debt to equity: 0.74; Net margin: 6.8%; Gross margin: 71.3%; Operating margin: 25.1%; Return on assets: 2.2%; Return on equity: 4.9% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Next earnings report | Date: 2026-11-03; EPS estimate: $0.79 per share; Revenue estimate: $15.93B The date is our provider's estimate until the company confirms it. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) earnings calendar |
Data provided for informational purposes only.
ETFs that hold PFE
Funds in our ETF coverage that list PFE among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| PBPH ETF | 3.42% | |
| WisdomTree BioRevolution Fund (WDNA) | 2.50% | |
| Alger Russell Innovation ETF (INVN) | 2.39% | |
| LSV Disciplined Value ETF (LSVD) | 1.73% |